ATYR 1940

Drug Profile

ATYR 1940

Alternative Names: ATYR1940; HRS(1-506); HRS(I-506); Resolaris

Latest Information Update: 09 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator aTyr Pharma
  • Class Amino acyl-tRNA synthetases; Aminoacyltransferases; Biological proteins; Peptides; Proteins
  • Mechanism of Action Histidine-tRNA ligase modulators; T cell activation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Facioscapulohumeral muscular dystrophy; Limb girdle muscular dystrophies
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Facioscapulohumeral muscular dystrophy; Limb girdle muscular dystrophies
  • Preclinical Interstitial lung diseases
  • Research Duchenne muscular dystrophy

Most Recent Events

  • 02 May 2018 Pharmacodynamics data from a preclinical trial presented at the American Academy of Immunology (AAI) Annual Meeting
  • 15 Aug 2017 Adverse events data from the phase I/II 005 and 006 trials in Facioscapulohumeral muscular dystrophy released by aTYR Pharma
  • 15 Aug 2017 Efficacy data from phase I/II 005 and 006 trials in Facioscapulohumeral muscular dystrophy released by aTYR Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top